Grace Therapeutics Secures $4M in Additional Funding

jueves, 23 de octubre de 2025, 8:07 am ET1 min de lectura
GRCE--

Grace Therapeutics has secured $4.0 million in additional funding through the exercise of common warrants issued in a 2023 private placement. The company issued 1,345,464 new shares of common stock at an exercise price of $3.003 per share. The remaining common warrants have expired as the FDA has accepted the New Drug Application for GTx-104 for review.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios